154 related articles for article (PubMed ID: 1503929)
1. Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group.
Vormoor J; Ritter J; Creutzig U; Boos J; Heyen P; Ludwig WD; Harbott J; Löffler H; Schellong G
Br J Cancer Suppl; 1992 Aug; 18():S63-7. PubMed ID: 1503929
[TBL] [Abstract][Full Text] [Related]
2. [Incidence and prognostic significance of Auer rods in children with acute myeloid leukemia in the studies AML-BFM-78 and -83].
Vormoor J; Ritter J; Creutzig U; Schellong G
Klin Padiatr; 1989; 201(4):227-32. PubMed ID: 2674529
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic significance of eosinophilia in children with acute myeloid leukemia in the studies AML-BFM-78 and -83].
Creutzig U; Ritter J; Niederbiermann-Koczy G; Harbott J; Schellong G
Klin Padiatr; 1989; 201(4):220-6. PubMed ID: 2674528
[TBL] [Abstract][Full Text] [Related]
4. [Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group].
Creutzig U; Ritter J; Heyen P; Berthold F; Henze G; Kabisch H; Lampert F; Niethammer D; Riehm H; Schellong G
Klin Padiatr; 1992; 204(4):236-45. PubMed ID: 1518259
[TBL] [Abstract][Full Text] [Related]
5. [Improved results in the treatment of acute myeloid leukemia - Results of study AML-BFM-93 in East Germany with comparisons to the preceding studies AML-I-82 and AML-II-87].
Steinbach D; Dörffel W; Eggers G; Holfeld E; Kluba U; Krause I; Lauterbach I; Reiss T; Rieske K; Scharfe V; Schumacher R; Weigel H; Weinmann G; Zintl F; Hermann J
Klin Padiatr; 2001; 213(4):162-8. PubMed ID: 11528549
[TBL] [Abstract][Full Text] [Related]
6. [Acute myeloid leukemia in children with Down syndrome].
Creutzig U; Ritter J; Ludwig WD; Niemeyer C; Reinisch I; Stollmann-Gibbels B; Zimmermann M; Harbott J
Klin Padiatr; 1995; 207(4):136-44. PubMed ID: 7564143
[TBL] [Abstract][Full Text] [Related]
7. Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group.
Ritter J; Creutzig U; Schellong G
Leukemia; 1992; 6 Suppl 2():59-62. PubMed ID: 1578943
[TBL] [Abstract][Full Text] [Related]
8. [Acute myelogenous leukemia in children under 2 years of age: studies and treatment results in 23 children in the AML therapy study BFM-78].
Creutzig U; Schaaff A; Ritter J; Jobke A; Kaufmann U; Schellong G
Klin Padiatr; 1984; 196(3):130-4. PubMed ID: 6590922
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U
J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630
[TBL] [Abstract][Full Text] [Related]
10. [Current results of cooperative AML therapy studies in children: BFM-78 and 83].
Creutzig U; Ritter J; Budde M; Riehm H; Henze G; Lampert F; Gerein V; Müller-Weihrich S; Niethammer D; Spaar HJ
Klin Padiatr; 1986; 198(3):183-90. PubMed ID: 3523024
[TBL] [Abstract][Full Text] [Related]
11. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
[TBL] [Abstract][Full Text] [Related]
12. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of chemotherapy alone with allogeneic bone marrow transplantation in first full remission in children with acute myeloid leukemia in the AML-BFM-83 and AML-BFM-87 studies--matched pair analysis].
Creutzig U; Bender-Götze C; Klingebiel T; Ebell W; Friedrich W; Stollmann-Gibbels B; Schmidt H; Suttorp M; Gratwohl A; Heyen P
Klin Padiatr; 1992; 204(4):246-52. PubMed ID: 1518260
[TBL] [Abstract][Full Text] [Related]
14. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations.
Gerr H; Zimmermann M; Schrappe M; Dworzak M; Ludwig WD; Bradtke J; Moericke A; Schabath R; Creutzig U; Reinhardt D
Br J Haematol; 2010 Apr; 149(1):84-92. PubMed ID: 20085575
[TBL] [Abstract][Full Text] [Related]
15. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
[TBL] [Abstract][Full Text] [Related]
16. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
[TBL] [Abstract][Full Text] [Related]
17. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
18. [Consolidation of therapy of acute myeloid leukemia with the AML-BFM 93 protocol in children in the Czech Republic].
Starý J; Gajdos P; Blazek B; Ptoszková H; Hrstková H; Kopecná L; Tousovská K; Hak J; Procházková D; Cerná Z; Jabali Y; Timr P; Vávra V; Sedlácek P; Smísek P; Hrusák O; Michalová K
Cas Lek Cesk; 2004; 143(4):257-63. PubMed ID: 15218726
[TBL] [Abstract][Full Text] [Related]
19. [Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies].
Ludwig WD; Teichmann JV; Sperling C; Komischke B; Ritter J; Reiter A; Odenwald E; Sauter S; Riehm H
Klin Padiatr; 1990; 202(4):243-52. PubMed ID: 2203938
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
Creutzig U; Zimmermann M; Ritter J; Reinhardt D; Hermann J; Henze G; Jürgens H; Kabisch H; Reiter A; Riehm H; Gadner H; Schellong G
Leukemia; 2005 Dec; 19(12):2030-42. PubMed ID: 16304570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
